Acomplia Approval Sverige
AcompliaThe medical research has shown a great interest in the last year to develop new drugs that will solve the obesity problem. Since a great percentage of the population in the developed countries wants to lose weight, the new trend is understandable because it can bring a lot of money, if such a drug is efficient. As early as 1994, the researchers in Sanofi-Aventis have started to create what it is called in the pharmaceutical world as Rimonabant. This is a CB1 cannabinoid receptor antagonist and can reduce you appetite. Therefore you lose weight.
Sanofi made some tests in 2001-2005 for over 6,600 patients and after some positive results they started to get the procedures for its selling on a world-wide scale. Under the brand name of Acomplia, they have obtained in 2006 from the European Union the authorization for marketing the new product in Europe as an adjunct to diet and exercise for the treatment of obese patients (BMI = 30 kg/m2), or overweight patients (BMI = 27 kg/m2). The new drug has shown remarkable results for patients with diabetes. Moreover it is discussed now in some countries - such as France - if Acomplia could be reimbursed by health insurance companies and state social security plans. Probably this will be the case just a limited number of obese patients, only the ones with type 2 diabetes.
Now, you can find it also in online pharmacies with distribution all over Europe.
Buy Xenical USA, Canada/ Buy Xenical UK Rest world
Buy Reductil UK Rest world
Buy Alli Diet Pill
Buy Hoodia Diet Pills
|
Acomplia
Menu 
